CK-869
CK-869 is an Actin-Related Protein 2/3 (ARP2/3) complex inhibitor, with an IC50 of 7 μM.
Product Specifications
CAS Number
388592-44-7
UNSPSC
12352005
Hazard Statement
H302, H361, H372, H410
Target
Arp2/3 Complex
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/CK-869.html
Purity
99.94
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C1N(C2=CC=C(OC)C=C2OC)C(C3=CC=CC(Br)=C3)SC1
Molecular Formula
C17H16BrNO3S
Molecular Weight
394.28
Precautions
H302, H361, H372, H410
References & Citations
[1]Hetrick B, et al. Small molecules CK-666 and CK-869 inhibit actin-related protein 2/3 complex by blocking an activating conformational change. Chem Biol. 2013 May 23;20 (5) :701-12.|[2]Yamagishi Y, et al. Use of CK-548 and CK-869 as Arp2/3 complex inhibitors directly suppresses microtubule assembly both in vitro and in vivo. Biochem Biophys Res Commun. 2018 Feb 12;496 (3) :834-839.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
032366-ML650 100 µL
B4GALT6, CT (B4GALT6, Beta-1,4-galactosyltransferase 6, UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 6, UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 6, Glucosylceramide beta-1,4-galactosyltransferase, Lactosylceramide synthase, UDP-Gal:glucosylceramide beta-1,4-galactosyltransferase) (MaxLight 650) discontinued
Sign In for Pricing
View Details 
247608-AP 100 µL
IL6 (Interleukin 6 (Interferon, beta 2), BSF2, HGF, HSF, IFNB2, IL-6) (AP) discontinued
Sign In for Pricing
View Details